Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 81 publications
Circulating Tumor DNA and Tissue Testing for Pancreatobiliary Tumors.
Journal: JAMA network open
Published: September 12, 2025
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial.
Journal: Hepatology (Baltimore, Md.)
Published: November 14, 2024
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 05, 2024
Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma.
Journal: ESMO open
Published: November 04, 2024
Combining Radioembolization and Immune Checkpoint Inhibitors for the Treatment of Hepatocellular Carcinoma: The Quest for Synergy.
Journal: Journal of vascular and interventional radiology : JVIR
Published: August 05, 2024
ERBB2 (HER2) amplifications and co-occurring KRAS alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition.
Journal: Frontiers in oncology
Published: November 15, 2023
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).
Journal: Future oncology (London, England)
Published: September 06, 2023
The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma.
Journal: JCO precision oncology
Published: August 10, 2023
Pharmacotherapeutic options for pancreatic ductal adenocarcinoma.
Journal: Expert opinion on pharmacotherapy
Published: November 17, 2022
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 09, 2022
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
Journal: NEJM evidence
Published: August 01, 2022
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma.
Journal: Journal of the National Cancer Institute
Published: July 28, 2022
Last Updated: 09/26/2026